U-M receives NIH grant for Risk Evaluation and Education for Alzheimer's Disease study

NewsGuard 100/100 Score

In a first-of-its kind study, University of Michigan researchers will provide genetic testing and Alzheimer's risk estimates for people who are already experiencing mild cognitive impairment.

Researchers hope to learn how people with mild cognitive impairment and their caregivers respond to health education and genetic testing, says Scott Roberts, associate professor in the Department of Health Behavior and Health Education at the U-M School of Public Health.

Roberts and colleagues will look specifically at how the information impacts the participants' psychological adjustment and any behavior changes, and evaluate how well the participants understand the study genetic testing and Alzheimer's risk assessment materials.

Mild cognitive impairment is a common condition where those affected have noticeable memory and thinking problems but can still carry out their usual activities. People with mild cognitive impairment are at elevated risk for developing Alzheimer's disease within five years, so it's important to evaluate the different methods of providing risk information for Alzheimer's, including genetic testing, to those individuals and their loved ones, Roberts says. After receiving their risk estimate, participants will be followed for a period of 12 months.

The study, called the Risk Evaluation and Education for Alzheimer's Disease, is a multi-centered research project funded by the National Institutes of Health.

Study participants will have the opportunity to learn what it means to have mild cognitive impairment, what their chances are of developing Alzheimer's, and how to cope with problems related to memory loss.

Source: University of Michigan School of Public Health

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity